Long Acting Muscarinic Antagonists (LAMA) such as tiotropium and glycopyrronium are used in the management of COPD1. They have been shown to improve lung function, quality of life and exercise tolerance. They have also been associated with reduced COPD-related exacerbations, associated hospitalisati...ons and duration of hospital stay. Both the South African Thoracic Society (SATS) and Global Initiative for Chronic Obstructive Lung Disease (GOLD), guidelines recommend the use of long acting anticholinergic drugs (or long acting beta agonists) in moderate to very severe disease as defined by lung function (FEV1). The most up to date guideline, utilizing the GRADE methodology (European Respiratory Society guidelines of 2017), confirms their superiority over long acting β agonists (LABA) as monotherapy for COPD in that LAMA's have demonstrated greater efficacy in terms of exacerbation reduction, with similar safety profile.2 These recommnedations are supported by published peer-reviewed
evidence including individual papers and Cochrane reviews.
more
According to the World Health Organization (WHO), sub-Saharan Africa has only 3% of the world’s health workers to cater for 11% of the world population, bearing over 25% of the global disease burden (WHO, 2014). With a steady increase in reported cases on the African Continent, the current COVID-1...9 pandemic threatens to overwhelm our already taxed health infrastructure. It is, therefore, imperative to take serious and urgent measures towards disease management and monitoring especially as the need for self-quarantine and contact surveillance rises.
In view of the infrastructural and resource gaps, technology should be considered for remote management of healthcare deliver to patients during this period. As it is abundantly clear, even countries with more advanced healthcare infrastructure and resources have struggled to treat COVID-19 and non-COVID-19 patients during this pandemic.
more
This toolkit for integrated vector management (IVM) is designed to help national and regional programme managers coordinate across sectors to design and run large IVM programmes.
The toolkit provides the technical detail required to plan, implement, monitor and evaluate an IVM approach. IVM can... be used when the aim is to control or eliminate vector-borne diseases and can also contribute to insecticide resistance management. This toolkit provides information on where vector-borne diseases are endemic and what interventions should be used, presenting case studies on IVM as well as relevant guidance documents for reference.
The diseases that are the focus of this toolkit are malaria, lymphatic filariasis, dengue, leishmaniasis, onchocerciasis, human African trypanosomiasis and schistosomiasis. It also includes information on other viral diseases (Rift Valley fever, West Nile fever, Chikungunya, yellow fever) and trachoma. If other vector-borne diseases appear in a country or area, vector control with an IVM approach should be adopted, as per national priorities.
more
Guide to access the National AMR Surveillance Dashboard
16 Dec. 2020
This document provides guidance to Ministries of Health (MOHs), laboratory personnel and implementing partners in African Union Member States on the application of rapid antigen tests to COVID-19 testing. The guidance serves as reference for policymakers, laboratory leads, implementing... partners, and experts on use case scenarios and associated testing algorithms for COVID-19 antigen tests. It recommends the use of antigen tests to increase access to testing and enable timely results for persons with or without symptoms in specific settings. The document will be reviewed and updated as more evidence becomes available regarding the use of rapid antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from global studies and evaluation efforts.
more
DOI 10.15252/emmm.201404792 |Published online 30.12.2014
EMBO Molecular Medicine(2014)emmm.201404792
Programme Brief
Accessed: 21.08.2019
MEDBOX has gathered a selection of over 60 African hits from different countries into a play list with the aim of raising awareness on the diverse ways to fight COVID-19 in addition to a COVID-19 Toolbox https://www.covid19box.org with all the up to date information on the pandemic. Feel free to pa...ss it onto your contacts, the poster can be printed and used in different settings such as cultural centers, hospitals and refugee camps. To the COVID-19 African hist playlist visit: https://www.youtube.com/playlist?list=PLQvyjafXneiihYMqxMmrQLD_iwXvi3eiT.
Enjoy empowerment and rhythm! Spread the music, not the virus!
more
South Africa is a mineral-rich country. Although the mining of these minerals generates wealth for the country, it also causes diseases in the mine workers who are exposed to harmful dust. Pulmonary silicosis, the disease most commonly caused by exposure to crystalline silica dust, was described in ...South African gold miners in the early 1900s not many years after gold-mining commenced. Most studies since then have been cross-sectional, with only one large cohort study being conducted on white miners; long-term trends have not been reported. Currently, South Africa has one of the highest rates of silicosis in the world.
more
Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States.
Currently..., there is:
1. No scientific evidence from pre-clinical studies on the therapeutic effect of ivermectin for the management of COVID-19;
2. No evidence of its clinical efficacy for the management of patients with asymptomatic, mild, moderate or severe COVID-19; and
3. No safety data regarding the use of ivermectin for COVID-19 in the majority of the published studies.
more
Updated 25 March 2020 (25 Maart 2020)
To eliminate lymphatic filariasis (LF) by 2020, the World Health Organization (WHO) has launched a campaign against the disease. Since the launch in 2000, significant progress has been made to achieve this ambitious goal. In this article we review the progress and status of the LF programme in Afric...a through the WHO neglected
tropical diseases preventive chemotherapy databank, the Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN) portal and other publications. In the African Region there are 35 countries endemic for LF. The Gambia was reclassified as not requiring preventive chemotherapy in 2015, while Togo and Malawi eliminated LF as a public health problem in 2017 and 2020, respectively. Cameroon discontinued mass drug administration (MDA) and transitioned to post-MDA surveillance to validate elimination. The trajectory of coverage continues to accelerate; treatment coverage increased from 0.1% in 2000 to 62.1% in 2018. Geographical coverage has also significantly increased, from 62.7% in 2015 to 78.5% in 2018. In 2019, 23 of 31 countries requiring MDA achieved 100% geographic coverage. Although much remains to be done, morbidity management and disability prevention services have steadily increased in recent years. Vector control interventions conducted by other programmes, particularly malaria vector control, have had a profound effect in stopping transmission in some endemic countries in the region. In conclusion, significant progress has been made in the LF programme
in the region while we identify the key remaining challenges in achieving an Africa free of LF.
more
Communication sur les risques et participation Communautaire
ي الغرض من إطار عمل إجراءات المراقبة القائمة عىل األحداث هو أن به
ن
تستعي السلطات والوكاالت المسؤولة عن المراقبة
ُ واالستجابة. كما
تيب إرشال تعىل سبيل المثال؛ هذ...ه الوثيقة ألصحاب المصلحة
ي
ُ
ُعد بمثابة ك
ا عاما ي
إطار استخدام
ي
الذين يرغبون ف ن
نهج "صحة واحدة" متعدد القطاعات لتنفيذ المراقبة القائمة عىل األحداث . و للقيام بذلك، تشتمل الوثيقة عىل فصول وملحق
ن مرتبطة ويمكن
للمستخدمي تغييها وتحديثها
بناء عىل احتياجاتهم الخاصة.
ُعد هذه
الت ي وت نسخة منقحة من النسخة األصلية "إطار عمل المراقبة القائمة عىل األحداث"
عام
ي
ن صدرت
ف 2018 .و ال ينسخ إطار
العمل هذا أو يحل محل أي مواد أخرى متاحة حاليا في ما يتعلق بمج ال المراقبة القائمة عىل األحداث أن
ن ؛ وبدال من ذلك، ينبعي
يستند إطار العمل إل الوثائق الموجودة سابقا ذات الصلة أو مرتبطة وأن يكون تيب
ُ
ك ا إرشاديا عملي ا لتنفيذ المراقبة القائمة عىل
األحداث أفريقيا.
ي
ن
ف ويتوافق إطار العمل ك لمنظمة الصحة العالمية
المشي
ي
هذا مع الطبعة الثالثة من التقييم الخارج فيما يتعلق
ر بالمؤشات التالية: تعزيز
ي عىل كشف األحداث ذات األهمية للصحة العامة واألمن الصح أنظمة المراقبة و اإلنذار المبكر القادر ة
ر المؤش )
حسنة والتعاون عي القطاعات وبين 1.D2)؛ مستويات استجابة الصحة العمومية الوطنية والمتوسطة
ُ
وقنوات االتصال الم
العامة واألمن الصح والمحلية فيما يتعلق بمراقبة األحداث ذات األهمية للصحة
ي
ر )المؤش
ن 2.D2)؛ القدرة عىل
وتحسي تحليل
ن البيانات عىل المستوى المتوسط والوطت ي
ر )المؤش
رش 3.D2 .)باإلضافة إل وع
الدول تنفيذ و
ي
ن
ف عرض مهام ووظائف المراقبة
القائمة عىل األحداث إذ ، اللوائح الصحية
ي
درجات التقييم المشي ك وإحراز تقدم نحو تلبية المتطلبات المبينة ف ن
ي
ستضمن زيادة ف ن
الدولية
.
تحسين أيضا، تنفيذ المراقبة المتكاملة لألمراض واالستجابة لها، وذلك بالنسبة
ي
ن
تعد هذه الوثيقة مكملة ويمكن أن تساعد ف ل لدول
ا
ي
االتحاد األفريق
ي
ن
اعتمدت االسي األعضاء ف اتيجية المتكاملة لمراقبة األمراض واالستجابة لها،
لت عىل وجه الخصوص ي
بالنسبة
للطبعة الثالثة ) 2019 تتضمن أجزاء حول
( الت المراقبة القائمة عىل األحداث ي
.
more